| Document |
Document Title |
|
WO/2024/080236A1 |
Food, drink, and antimicrobial agent according to the present invention contain at least one of six natural product-derived compounds represented by formulas 1-6 described in the description, or salts thereof. These compounds are each a ...
|
|
WO/2024/065907A1 |
Provided are a pentacyclic triterpene saponin derivative, a preparation method therefor, and a use thereof. A compound A3 is used as a raw material, a derivative is prepared by targeting a carboxyl group of C-28 and using an esterificati...
|
|
WO/2024/067327A1 |
The present invention relates to use of a triterpenoid saponin compound with a general formula structure represented by formula A in the preparation of a medicament for preventing and/or treating nodule, fibrosis, or granuloma diseases, ...
|
|
WO/2024/015416A1 |
The present disclosure relates to compounds that are derivatives of the compound, celastrol, of formula (I), wherein R is an amide group and pharmaceutical compositions that include these celastrol derivative compounds. The disclosure al...
|
|
WO/2024/005485A1 |
The present disclosure provides a saponin derivative compound, a pharmaceutical composition for preventing or treating coronavirus infection comprising same, and a composition for inhibiting coronavirus entry into cells. A saponin deriva...
|
|
WO/2023/226904A1 |
Provided are an intestinal tract targeted pentacyclic triterpene TGR5 receptor agonist, a preparation method therefor and a use thereof. The structure is as shown in formula (I). The compound can be used for preparing drugs for treating ...
|
|
WO/2023/225457A1 |
The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, m...
|
|
WO/2023/213264A1 |
The present invention relates to a novel oleanamide derivative for activating a KEAP/NRF2/ARE signaling pathway. The compound of the present invention is represented by general formula (I), wherein L, R3, R4, Z, and n are set forth in th...
|
|
WO/2023/205850A1 |
The present invention relates to methods and uses for producing an insulin-producing cell from a pancreatic exocrine cell comprising contacting the pancreatic exocrine cell with an inhibitor of EZH2. The present invention also relates to...
|
|
WO/2023/192574A1 |
A method of preparing a triterpenoid compound of formula (I): formula (I), including a step of converting a compound of formula (II) into the compound of formula (I), formula (II) wherein R1 and R2 independently represent hydrogen or a p...
|
|
WO/2023/151292A1 |
The present invention relates to 3α-triazole-oleanolic acid derivatives, a preparation method therefor, and the uses of said derivatives serving as hyaluronidase inhibitors and used for preparing anti-aging cosmetic products. Specifical...
|
|
WO/2023/149727A1 |
Betulin is a natural pentacyclic triterpene, and is contained in birch tree, especially its outer bark. Betulin can be used as a hydrophobic building block for production of biobased surfactants. This invention is related to amphiphilic ...
|
|
WO/2023/099741A1 |
The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions th...
|
|
WO/2023/086467A1 |
The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative ...
|
|
WO/2023/078004A1 |
The present application relates to the field of compounds, and in particular, to matrine glycyrrhizine amino acid ionic salt, a preparation method therefor and an application thereof. The cation of the matrine glycyrrhizine amino acid io...
|
|
WO/2023/036404A1 |
The invention relates to novel compounds according to formula (I), a method for producing such a compound, a mixture comprising such a compound, a composition for food or pleasure or a pharmaceutical composition comprising one or more su...
|
|
WO/2023/028278A2 |
Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I) : and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are con...
|
|
WO/2023/015548A1 |
Disclosed in the present invention are a compound, and a preparation method therefor and the use thereof. The compound provided by the present invention is isolated from an ethyl acetate extraction part of Actinidia chinensis Planch root...
|
|
WO/2023/011276A1 |
The present invention relates to the technical field of biomedicine, particularly to a class of CDDO/tetramethylpyrazine alcohol heterocomplexes having a combination therapy effect, and a preparation method therefor and the use thereof, ...
|
|
WO/2022/268235A1 |
The present invention relates to the technical field of plant extraction, and in particular relates to a saponin composition having high stability and a preparation method therefor. The saponin composition is extracted from natural plant...
|
|
WO/2022/228352A1 |
Provided are a pentacyclic triterpenoid crystal and a preparation method therefor. The pentacyclic triterpenoid compound is 3-O-cyclohexanyl-11-carbonyl-β-boswellic acid, abbreviated as CKBA. The preparation method for the compound crys...
|
|
WO/2022/221393A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, TLR4 agonists and antagonists, TLR9 agonists and antagonists, and combinations thereof, as well as pharmaceutical compositions comprising the foregoing an...
|
|
WO/2022/151002A1 |
A glycyrrhetinic acid derivative represented by formula (I), a synthesis method therefor, a pharmaceutical composition thereof and a use thereof. The foregoing glycyrrhetic acid derivative has a structure as represented by formula (I), a...
|
|
WO/2022/155614A1 |
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...
|
|
WO/2022/124840A1 |
The present invention provides a sea cucumber genital gland extract, preferably, a novel saponin compound separated from an ovary extract, and the novel use of a sea cucumber genital gland extract or a compound separated from a sea cucum...
|
|
WO/2022/056439A1 |
The present disclosure relates to synthetic triterpenoids, methods for preparing such synthetic triterpenoids, and methods of using such synthetic triterpenoids to treat and/or prevent diseases or disorders such as cancers, particularly ...
|
|
WO/2022/041126A1 |
Provided are a glycyrrhizic acid derivative represented by formula (I) and a pharmaceutical composition thereof. The symbols in formula (I) are as defined in the description. Same can inhibit flaviviruses, such as dengue virus and Zika v...
|
|
WO/2022/031359A1 |
Substantially pure saponin extracts and orthogonal chromatographic methods for purification of saponin extracts are disclosed. The purified saponin extracts may include QS-21 and can have a purity of greater than 97%. The orthogonal chro...
|
|
WO/2022/031130A1 |
The present invention relates to an ester derivative precursor drug of inotodiol and a use thereof. The precursor drug has an increased solubility in an inorganic solvent and an organic solvent and an improved stability and as such, can ...
|
|
WO/2022/007765A1 |
The present invention provides a pentacyclic triterpenoid glycoside compound, and a preparation method therefor and a use thereof. Specifically, the present invention provides a compound as shown in formula I. The definition of each grou...
|
|
WO/2022/006145A1 |
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/240349A1 |
The present invention relates to a method for the production of high amounts of triterpenic acids by an in vitro culture of calluses deriving from the pulp of apples of Red Sentinel (RS) variety, and to in vitro cultures of calluses deri...
|
|
WO/2021/179884A1 |
The present invention belongs to the field of the pharmaceutical chemistry, and particularly relates to an oleanolic acid derivative having a conjugated diene structure C ring, and a preparation method therefor and the use thereof. In pa...
|
|
WO/2021/161206A1 |
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n, and ring (II) are as defined in formula (I). The invention also relates to novel trit...
|
|
WO/2021/139395A1 |
Disclosed is a high-efficiency low-toxicity anti-cancer compound synthesized by autocatalysis in cells and living bodies. The anti-cancer compound is prepared by means of chemical synthesis of a metal complex precursor and an organic act...
|
|
WO/2021/134408A1 |
The present invention relates to preparation, impurity removal and purification methods for glycyrrhizic acid monovalent salt. The preparation method for glycyrrhizic acid monovalent salt comprises mixing a glycyrrhizinate mixture and a ...
|
|
WO/2021/134407A1 |
A method for extracting a crude product of glycyrrhizic acid and glycyrrhizic flavone from licorice and purifying to obtain glycyrrhizinate. In the method, a medicinal material of licorice and an organic solvent are mixed at a certain ra...
|
|
WO/2021/122998A1 |
The present invention relates to novel saponins of formula (I), comprising acetyl residues on two of their sugar residues. These saponins are able to enhance the transfection efficiency to a high extent and show much less cytotoxic side ...
|
|
WO/2021/127480A1 |
In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions pro...
|
|
WO/2021/109836A1 |
Disclosed in the present invention are a tea saponin compound, a preparation method therefor, and an application thereof. The structural general formula of the tea saponin compound is as represented by formula (I). It is proved in the pr...
|
|
WO/2021/104391A1 |
The present invention relates to the field of pharmaceutical chemistry and the field of pharmacotherapeutics, and in particular, to a 2-cyano-3,12-dioxooleanane-1,9(11)-diene-17-cinnamamide derivative and a preparation method therefor; a...
|
|
WO/2021/085291A1 |
The purpose of the present invention is to provide: a composition for TGR5 activation, said composition comprising, as an active ingredient, a substance that has an effect of activating TGR5 and shows a high selectivity for TGR5; and a m...
|
|
WO/2021/078150A1 |
A pentacyclic triterpene TGR5 receptor agonist and a preparation method therefor and uses thereof. The structure of the pentacyclic triterpene TGR5 receptor agonist is as shown in formula I, and the definition of each substituent group i...
|
|
WO/2021/047672A1 |
Disclosed herein are triterpenoid compounds, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also disclosed herein are methods of their use for treat.
|
|
WO/2021/016191A1 |
Disclosed herein are compounds of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidan...
|
|
WO/2020/259205A1 |
Disclosed are derivatives of novel pentacyclic triterpenoid AMPK agonists, oleanolic acid and δ-oleanolic acid, and medicinal use thereof, specifically, a compound represented by formula I or formula II, and a pharmaceutically acceptabl...
|
|
WO/2020/264509A1 |
Provided herein is a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VII, VIII, IX, or XI: or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, II, IlIa, IlIb, V, VIa, VIb, VI...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
